202 related articles for article (PubMed ID: 1717988)
1. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.
Romero DL; Busso M; Tan CK; Reusser F; Palmer JR; Poppe SM; Aristoff PA; Downey KM; So AG; Resnick L
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8806-10. PubMed ID: 1717988
[TBL] [Abstract][Full Text] [Related]
2. (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.
Olmsted RA; Slade DE; Kopta LA; Poppe SM; Poel TJ; Newport SW; Rank KB; Biles C; Morge RA; Dueweke TJ; Yagi Y; Romero DL; Thomas RC; Sharma SK; Tarpley WG
J Virol; 1996 Jun; 70(6):3698-705. PubMed ID: 8648704
[TBL] [Abstract][Full Text] [Related]
3. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors.
Vasudevachari MB; Battista C; Lane HC; Psallidopoulos MC; Zhao B; Cook J; Palmer JR; Romero DL; Tarpley WG; Salzman NP
Virology; 1992 Sep; 190(1):269-77. PubMed ID: 1382341
[TBL] [Abstract][Full Text] [Related]
4. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
Yuasa S; Sadakata Y; Takashima H; Sekiya K; Inouye N; Ubasawa M; Baba M
Mol Pharmacol; 1993 Oct; 44(4):895-900. PubMed ID: 7694070
[TBL] [Abstract][Full Text] [Related]
5. Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.
Gu Z; Quan Y; Li Z; Arts EJ; Wainberg MA
J Biol Chem; 1995 Dec; 270(52):31046-51. PubMed ID: 8537362
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the anti-HIV-1 activity of 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), new non-nucleoside reverse transcriptase inhibitors.
Tramontano E; Marongiu ME; de Montis A; Loi AG; Artico M; Massa S; Mai A; la Colla P
New Microbiol; 1994 Oct; 17(4):269-79. PubMed ID: 7532270
[TBL] [Abstract][Full Text] [Related]
7. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Chong KT; Pagano PJ; Hinshaw RR
Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
[TBL] [Abstract][Full Text] [Related]
8. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG
Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109
[TBL] [Abstract][Full Text] [Related]
9. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors.
Buckheit RW; Fliakas-Boltz V; Decker WD; Roberson JL; Pyle CA; White EL; Bowdon BJ; McMahon JB; Boyd MR; Bader JP
Antiviral Res; 1994 Sep; 25(1):43-56. PubMed ID: 7529014
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
[TBL] [Abstract][Full Text] [Related]
11. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; De Clercq E
Virology; 1993 Oct; 196(2):576-85. PubMed ID: 7690501
[TBL] [Abstract][Full Text] [Related]
12. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
McMahon JB; Buckheit RW; Gulakowski RJ; Currens MJ; Vistica DT; Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz RJ; Brouwer WG; Felauer EE; Boyd MR
J Pharmacol Exp Ther; 1996 Jan; 276(1):298-305. PubMed ID: 8558446
[TBL] [Abstract][Full Text] [Related]
13. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5'-triphosphates of various anti-HIV nucleoside analogs.
White EL; Parker WB; Ross LJ; Shannon WM
Antiviral Res; 1993 Dec; 22(4):295-308. PubMed ID: 7506513
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.
Fan N; Evans DB; Rank KB; Thomas RC; Tarpley WG; Sharma SK
FEBS Lett; 1995 Feb; 359(2-3):233-8. PubMed ID: 7532595
[TBL] [Abstract][Full Text] [Related]
15. Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.
Gu Z; Li X; Quan Y; Parniak MA; Wainberg MA
J Virol; 1996 Apr; 70(4):2620-6. PubMed ID: 8642696
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
[TBL] [Abstract][Full Text] [Related]
17. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of HIV-1 reverse transcriptase and fidelity of in vitro DNA replication.
Abbotts J; Wilson SH
J Enzyme Inhib; 1992; 6(1):35-46. PubMed ID: 1285301
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
Okamoto M; Okamoto T; Baba M
Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
